RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.

[1]  Ying Wang,et al.  ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. , 2019, Blood advances.

[2]  Jonathan M Marron,et al.  Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia? , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Hsuan-Ting Huang,et al.  Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. , 2019, Cancer discovery.

[4]  Anna L. Brown,et al.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution , 2019, Leukemia.

[5]  Matthew T. Patrick,et al.  Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC , 2019, Front. Genet..

[6]  T. Haferlach,et al.  Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML , 2019, International journal of molecular sciences.

[7]  M. Fleming,et al.  Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy , 2019, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[8]  S. K. Zaidi,et al.  RUNX1‐dependent mechanisms in biological control and dysregulation in cancer , 2018, Journal of cellular physiology.

[9]  K. Réblová,et al.  C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies , 2018, International Journal of Hematology.

[10]  Motomi Osato,et al.  Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation , 2018, Biomarker Research.

[11]  V. Rocha,et al.  Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia. , 2018, Cancer genetics.

[12]  T. Haferlach,et al.  Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML , 2018, Leukemia.

[13]  G. Boucher,et al.  Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity , 2017, Clinical Cancer Research.

[14]  M. Patnaik,et al.  Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia , 2017, Leukemia & lymphoma.

[15]  W. Xin,et al.  Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation , 2017, Haematologica.

[16]  P. Noris,et al.  Mutations of RUNX1 in families with inherited thrombocytopenia , 2017, American journal of hematology.

[17]  J. Fitzgibbon,et al.  Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree , 2017, European Journal of Human Genetics.

[18]  A. Paterson,et al.  Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  R. Sood,et al.  Role of RUNX1 in hematological malignancies. , 2017, Blood.

[20]  Anna L. Brown,et al.  Recognition of familial myeloid neoplasia in adults. , 2017, Seminars in hematology.

[21]  J. Jansen,et al.  Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders. , 2017, Blood.

[22]  M. Wlodarski,et al.  Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants , 2017, Leukemia.

[23]  N. Young,et al.  Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes , 2017, Leukemia.

[24]  L. Bullinger,et al.  Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis , 2017, Leukemia.

[25]  W. Vainchenker,et al.  Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0 , 2016, Journal of cellular and molecular medicine.

[26]  J. Klco,et al.  The genomic landscape of pediatric myelodysplastic syndromes , 2016, Nature Communications.

[27]  S. Langabeer,et al.  Targeted next‐generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia , 2016, British journal of haematology.

[28]  S. Mundell,et al.  Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects , 2016, Haematologica.

[29]  J. Orange,et al.  Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). , 2016, Clinical lymphoma, myeloma & leukemia.

[30]  M. Walter,et al.  ‘CHIP’ping away at clonal hematopoiesis , 2016, Leukemia.

[31]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[32]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[33]  H. Kestler,et al.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features , 2016, Leukemia.

[34]  P. Nurden,et al.  Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders , 2016, Orphanet Journal of Rare Diseases.

[35]  O. Abdel-Wahab,et al.  Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia , 2016, Leukemia.

[36]  E. Ito,et al.  Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  C. Dinardo,et al.  Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. , 2016, American journal of clinical pathology.

[38]  S. Miyano,et al.  Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele , 2016, Blood Cancer Journal.

[39]  T. Suda,et al.  RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity , 2016, Blood Cancer Journal.

[40]  K. Goi,et al.  Analyses of Genetic and Clinical Parameters for Screening Patients With Inherited Thrombocytopenia with Small or Normal‐Sized Platelets , 2015, Pediatric blood & cancer.

[41]  Christopher A. Miller,et al.  Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. , 2015, Blood.

[42]  G. Tamiya,et al.  Whole-exome sequencing confirmation of a novel heterozygous mutation in RUNX1 in a pregnant woman with platelet disorder , 2015, Platelets.

[43]  X. Estivill,et al.  Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility , 2015, Nature Communications.

[44]  Marilyn M. Li,et al.  Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome , 2015, Leukemia research reports.

[45]  I. Lewis,et al.  A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone , 2015, Leukemia.

[46]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[47]  David A. Williams,et al.  Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity , 2015, Haematologica.

[48]  A. Pezic,et al.  Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis , 2014, Pediatric Rheumatology.

[49]  Nicolai J. Birkbak,et al.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Y. Hayashi,et al.  Recurrent CDC25C mutations drive malignant transformation in FPD/AML , 2014, Nature Communications.

[51]  M. Simpson,et al.  Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. , 2013, Blood.

[52]  J. Weitzel,et al.  Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype. , 2012, International journal of clinical medicine.

[53]  T. Vulliamy,et al.  Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia , 2012, British journal of haematology.

[54]  M. Poot,et al.  Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees , 2012, Leukemia.

[55]  S. Ogawa,et al.  Brief Report Results and Discussion , 2022 .

[56]  D. Bluteau,et al.  Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. , 2011, Blood.

[57]  S. Schnittger,et al.  Childhood B‐cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation , 2010, British journal of haematology.

[58]  J. Fitzgibbon,et al.  A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals , 2010, European journal of haematology.

[59]  K. Onel,et al.  Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder , 2010, Leukemia & lymphoma.

[60]  N. Philip,et al.  Syndromic mental retardation with thrombocytopenia due to 21q22.11q22.12 deletion: Report of three patients , 2010, American journal of medical genetics. Part A.

[61]  M. Kurokawa,et al.  T cell acute lymphoblastic leukemia arising from familial platelet disorder , 2010, International journal of hematology.

[62]  A. Baruchel,et al.  High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. , 2009, Blood.

[63]  D. Steinemann,et al.  A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? , 2009, Leukemia.

[64]  S. Antonarakis,et al.  Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21 , 2009, European Journal of Human Genetics.

[65]  W. Berdel,et al.  Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene , 2009, Annals of Hematology.

[66]  Andrew Collins,et al.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.

[67]  B. Leber,et al.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. , 2008, Blood.

[68]  A. C. Chinault,et al.  Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. , 2008, Blood.

[69]  P. Chambon,et al.  Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions , 2008, European Journal of Human Genetics.

[70]  J. Fitzgibbon,et al.  Familial myelodysplasia and acute myeloid leukaemia – a review , 2007, British journal of haematology.

[71]  A. Ekici,et al.  Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays , 2007, Journal of Medical Genetics.

[72]  C. Pirola,et al.  Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. , 2005, Blood.

[73]  A. Rao,et al.  Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. , 2004, Blood.

[74]  Yusuke Nakamura,et al.  An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis , 2003, Nature Genetics.

[75]  Jurg Ott,et al.  A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis , 2003, Nature Genetics.

[76]  P. Ganly,et al.  A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia , 2002, British journal of haematology.

[77]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[78]  A. Hagenbeek,et al.  A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. , 2001, Blood.

[79]  Takashi Kumasaka,et al.  Structural Analyses of DNA Recognition by the AML1/Runx-1 Runt Domain and Its Allosteric Control by CBFβ , 2001, Cell.

[80]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[81]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[82]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[83]  E. van Binsbergen,et al.  Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. , 2010, Leukemia research.

[84]  H. Bengtsson,et al.  Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome , 2010, Leukemia.